Heron Bay Capital Management Takes Position in Definitive Healthcare Corp. (NASDAQ:DH)

Heron Bay Capital Management acquired a new stake in Definitive Healthcare Corp. (NASDAQ:DH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,719 shares of the company’s stock, valued at approximately $89,000.

Other institutional investors have also modified their holdings of the company. Massachusetts Financial Services Co. MA grew its stake in Definitive Healthcare by 36.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock worth $27,058,000 after purchasing an additional 1,626,813 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Definitive Healthcare during the 3rd quarter worth $512,000. Hennion & Walsh Asset Management Inc. grew its stake in Definitive Healthcare by 34.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock worth $209,000 after purchasing an additional 12,946 shares in the last quarter. Barclays PLC grew its stake in Definitive Healthcare by 318.8% during the 3rd quarter. Barclays PLC now owns 81,916 shares of the company’s stock worth $366,000 after purchasing an additional 62,354 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Definitive Healthcare by 431.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock worth $993,000 after purchasing an additional 180,323 shares in the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Stock Up 0.7 %

DH opened at $2.81 on Friday. The business has a 50 day moving average price of $4.19 and a two-hundred day moving average price of $4.31. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The company has a market cap of $317.28 million, a PE ratio of -0.91, a P/E/G ratio of 4.06 and a beta of 1.51. Definitive Healthcare Corp. has a 52 week low of $2.55 and a 52 week high of $8.35.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $62.29 million for the quarter, compared to analysts’ expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. As a group, research analysts anticipate that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on DH. Stephens began coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. The Goldman Sachs Group lowered their price objective on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Barclays lowered their price objective on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Definitive Healthcare currently has an average rating of “Hold” and a consensus price target of $5.35.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.